Skip to main
XGN

Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc (XGN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Exagen Inc has demonstrated strong financial performance, with its average selling prices (ASPs) increasing by 9% year-over-year to reach $441 per test, signaling positive pricing momentum. The company's revenue grew by 19% year-over-year over the past nine months, bolstered by balanced gains in ASPs and volumes, reflecting effective operational strategies and team leadership changes. Additionally, Exagen is strategically expanding its sales territories to 45 by the end of 2025, which is expected to further drive volume growth and enhance its revenue-generating capabilities.

Bears say

Exagen's financial outlook appears negative due to a lowered growth forecast for 2026, which is compounded by delays in achieving positive free cash flow and a decline in peer multiples. The company is facing challenges, including the loss of a direct bill account that contributed 2% to its volume, which has raised concerns about its growth trajectory and profitability timing. Additionally, the anticipated more muted average selling price (ASP) and gross margin expansion further exacerbate the company's revenue growth assumptions over the long term.

Exagen Inc (XGN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exagen Inc (XGN) Forecast

Analysts have given Exagen Inc (XGN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Exagen Inc (XGN) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exagen Inc (XGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.